AtaiBeckley Inc.
About AtaiBeckley Inc.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.1M
- Net income
- -$660.0M
- Total assets
- $292.7M
- Market cap
- $1.5B
- Operating margin
- -33341.2%
- Net margin
- -48717.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $308.0K
- Operating expenses
- $103.0M
- Operating income
- -$102.7M
- Income tax
- -$356.0K
- Net income
- -$150.0M
- EPS (basic)
- $-0.93
- EPS (diluted)
- $-0.93
Balance sheet
- Total assets
- $159.4M
- Current assets
- $80.1M
- Total liabilities
- $42.8M
- Current liabilities
- $25.0M
- Shareholders’ equity
- $116.6M
Cash flow
- Operating cash flow
- -$82.4M
- Investing cash flow
- $59.2M
- Financing cash flow
- $5.4M
- Net cash flow
- -$17.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-0.93
- Shares outstanding
- 384.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $660.0M in FY2025.
- Revenue declined 98% from FY2021 to FY2024.
- Trading 41% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AtaiBeckley Inc..
Write a review
News about AtaiBeckley Inc.
News & sentiment via Polygon.io
